AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01563237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIDI Arrow
Description: Implantation of MIDI Arrow
Study NCT06614699 — intervention group
Intervention type: OTHER
Intervention: abdominal fat and muscle area
Description: Abdominal fat and muscle area were calculated based on abdominal CT.
Study NCT02112656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
Study NCT02112656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy infusion
Description: Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
Study NCT01235689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
Study NCT01235689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
Study NCT01778413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRIPLA
Study NCT01778413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRIPLA
Study NCT01994876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 1
Description: Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
Study NCT01994876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test 2
Description: Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
Study NCT01186276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: Dietary fiber supplements to be consumed daily for 6 weeks.
Study NCT01186276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch
Description: Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
Study NCT00457626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Extemporaneous suspension of valsartan, orally.
Study NCT01005290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pill
Description: A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
Study NCT01005290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
Study NCT00946595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz/emtricitabin/tenofovir
Description: 1x600/200/245 mg per day (one tablet) between W0 et W98
Study NCT00946595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: 4 x 200/50 mg (4 tablets) once a day between W0 and W98
Study NCT01235689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
Study NCT01235689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
Study NCT01235689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Study NCT01235689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Study NCT00678093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of the SNAG technique
Description: SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
Study NCT03026361 — intervention group
Intervention type: GENETIC
Intervention: global proteomic profiling
Description: Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
Study NCT03167905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural delivery system
Description: Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
Study NCT03167905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entonox
Description: Entonox will be given upon request in non-epidural group.
Study NCT03167905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
Study NCT03605719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV
Study NCT02135341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
Study NCT02135341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
Study NCT03398837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg
Description: Subjects will receive lenabasum 5 mg twice daily.
Study NCT03398837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg
Description: Subjects will receive lenabasum 20 mg twice daily.
Study NCT03398837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Subjects will receive placebo twice daily.
Study NCT04402320 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
Study NCT04402320 — intervention group
Intervention type: DEVICE
Intervention: ventilator
Description: reconnected to mechanical ventilation before extubation for one hour with sedation
Study NCT02031471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Fixed dose of 162 mg subcutaneously weekly
Study NCT02857647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An information video
Description: Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
Study NCT03631368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
Study NCT02787317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
Study NCT02787317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Heparin is used in patients undergoing percutaneous coronary intervention.
Study NCT03427476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging.
Study NCT00686439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: subcutaneous injection 40mg on alternate weeks
Study NCT00686439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: subcutaneous injection 40mg every other week
Study NCT01343069 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implementation surgical checklist
Description: a checklist according to the suggestions raised by the WHO is implementated
Study NCT02385201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza
Description: Spinal Cord Stimulation
Study NCT00616044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous spinal anesthesia
Description: bupivacaina isobaric 0.5%, 5 mg
Study NCT00616044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinocath a catheter for continuous spinal anesthesia
Description: Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
Study NCT00616044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined spinal epidural anesthesia
Description: CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
Study NCT02168140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT02168140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV
Study NCT00556491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
Study NCT00556491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
Study NCT03618329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prehabilitation
Description: exercise, nutrition and anxiety reduction in the preoperative period
Study NCT03138824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPIES assisted TURBT
Description: SPIES assisted TURBT of NMIBC
Study NCT03138824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WLI assisted TURBT
Description: White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
Study NCT01473550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to TELUS Health Space and Smart Phone
Description: Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
Study NCT03746002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone 60 minutes prior to furosemide
Description: All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
Study NCT03746002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone concurrently with furosemide
Description: All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
Study NCT01709994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100 mg/day of aspirin
Study NCT03764735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose - SkQ1
Description: SkQ1 Low dose ophthalmic solution
Study NCT03764735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose - SkQ1
Description: SkQ1 High Dose ophthalmic solution
Study NCT03764735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SkQ1 (Vehicle)
Description: Vehicle for SkQ1 ophthalmic solution
Study NCT02216799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine Insulin
Description: 80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
Study NCT02216799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: 80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
Study NCT04060511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10342
Description: HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
Study NCT04177641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Disulphide(μmol/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study NCT04177641 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study NCT06331377 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT03910075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACQUIRE - High Dosage
Description: Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
Study NCT03910075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACQUIRE - Moderate Dosage
Description: Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
Study NCT03910075 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual & Customary Treatment (U&CT)
Description: Children in this group will receive the same U\&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
Study NCT04533945 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FreeStyle Libre
Description: The Freestyle Libre is a device worn on the back of the arm to measure glucose levels in the interstitial fluid. The device is applied by the patient and can be worn for 14 days, at which time it is replaced with a new device. The device does not require calibration with blood glucose testing. A scan with the receiver or a cell phone can be used to obtain glucose levels. The device does not alarm, so scanning is the only way for a patient to know if they are hypo or hyperglycemic. Studies have shown that the use of this technology can improve glycemic control as measured by Hemoglobin A1c and glucose variability in some patients. In addition, use of this technology in the outpatient setting has been associated with both improved patient satisfaction and increased glucose monitoring
Study NCT02716441 — intervention group
Intervention type: DEVICE
Intervention: Radio-opaque Tissue Markers
Description: All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
Study NCT03190421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Expanded Urinary Culture
Description: involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
Study NCT03190421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urine Culture (SUC)
Description: involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
Study NCT04500145 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SIB-IMRT
Description: 60Gy given to the tumor area，50Gy to the CR lesion or high-risk field at the same time
Study NCT04500145 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: routine IMRT
Description: patients received IMRT or VMAT，with the prescription of 60Gy/2Gy/30F to the planning tumor volume ，concurrent or sequential with EP chemotherapy
Study NCT02398331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardised information and education on sexuality in women with spinal cord injury
Description: Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~* Educational footage~* Clinical neurological examination with educational aim~* Structured consultation providing information on the physiology of sexual response in women with spinal cord injury
Study NCT02036346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Ηydration Solution
Description: Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
Study NCT02036346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advise on calculated oral fluid requirements
Study NCT02296619 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
Study NCT02296619 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A sham band-aid will be applied to the abdomen of subjects
Study NCT04483063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate skin cleanser
Description: 2% chlorhexidine gluconate skin cleanser over shoulder region before shoulder surgery
Study NCT02036346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No nutritional advice will be given